166 related articles for article (PubMed ID: 37894449)
1. Ultra-Hypofractionated Re-Irradiation with Anti-PD-1 Immunotherapy for Locoregionally Recurrent (after Radical Chemo-Radiotherapy) Non-Small Cell Lung Cancer.
Filippatos K; Koukourakis IM; Anevlavis S; Giaktzidis A; Koukourakis MI
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894449
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1 immunotherapy with dose-adjusted ultra-hypofractionated re-irradiation in patients with locoregionally recurrent head and neck cancer.
Koukourakis IM; Giakzidis AG; Koukourakis MI
Clin Transl Oncol; 2023 Oct; 25(10):3032-3041. PubMed ID: 37059932
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.
Theelen WSME; Chen D; Verma V; Hobbs BP; Peulen HMU; Aerts JGJV; Bahce I; Niemeijer ALN; Chang JY; de Groot PM; Nguyen QN; Comeaux NI; Simon GR; Skoulidis F; Lin SH; He K; Patel R; Heymach J; Baas P; Welsh JW
Lancet Respir Med; 2021 May; 9(5):467-475. PubMed ID: 33096027
[TBL] [Abstract][Full Text] [Related]
4. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
[No Abstract] [Full Text] [Related]
8. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM
Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935
[TBL] [Abstract][Full Text] [Related]
10. Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
Samuel E; Lie G; Balasubramanian A; Hiong A; So Y; Voskoboynik M; Moore M; Shackleton M; Haydon A; John T; Mitchell PLR; Markman B; Briggs P; Parakh S
Clin Lung Cancer; 2021 May; 22(3):e425-e430. PubMed ID: 32778511
[TBL] [Abstract][Full Text] [Related]
11. Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer.
Donato V; Arcangeli S; Monaco A; Caruso C; Cianciulli M; Boboc G; Chiostrini C; Rauco R; Pressello MC
Front Oncol; 2013; 3():286. PubMed ID: 24303369
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
13. Pooled analysis on image-guided moderately hypofractionated thoracic irradiation in inoperable node-positive/recurrent patients with non-small cell lung cancer with poor prognostic factors and severely limited pulmonary function and reserve.
Eze C; Guggenberger JE; Schmidt-Hegemann NS; Kenndoff S; Taugner J; Käsmann L; Schönecker S; Flörsch B; Li M; Belka C; Manapov F
Cancer; 2022 Jun; 128(12):2358-2366. PubMed ID: 35417563
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
[TBL] [Abstract][Full Text] [Related]
15. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated Volumetric-Modulated Arc Radiotherapy for Patients With Non-Small-Cell Lung Cancer Not Suitable for Surgery or Conventional Chemoradiotherapy or SBRT.
Shen J; Yang D; Chen M; Jiang L; Dong X; Li D; Yu R; Yu H; Shi A
Front Oncol; 2021; 11():644852. PubMed ID: 34221967
[TBL] [Abstract][Full Text] [Related]
17. Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
Sood S; Ganju R; Shen X; Napel MT; Wang F
Clin Lung Cancer; 2021 May; 22(3):e301-e312. PubMed ID: 33132058
[TBL] [Abstract][Full Text] [Related]
18. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Modestly Hypofractionated Radiation for Lung Tumors: Pre- and Mid-Treatment Positron Emission Tomography-Computed Tomography Metrics as Prognostic Factors.
Harris JP; Chang-Halpenny CN; Maxim PG; Quon A; Graves EE; Diehn M; Loo BW
Clin Lung Cancer; 2015 Nov; 16(6):475-85. PubMed ID: 25770888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
